Transparency initiative by the FDA's center for drug evaluation and research (CDER): Two qualitative studies of public perceptions

European Journal of Risk Regulation

Volumn 3, Issue 1, 2012, Pages 57-71

  Chakraborty, Sweta ^a   Lofstedt, Ragnar ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893436411     PISSN: 1867299X     EISSN: 21908249     Source Type: Journal    
DOI: 10.1017/S1867299X00001811     Document Type: Article

References (81)

1. Ragnar E. Lofstedt, "Risk communication and management in the twenty-first century", 7 International Public Management Journal (2004), pp. 335-346.
2. Eric Ashby and Mary Anderson, The Politics of Clean Air (Oxford: Oxford University Press, 1981).
3. Ronald Brickman, Sheila Jasanoff and Thomas Ilgen, Controlling Chemicals: The politics of regulation in Europe and United States (Ithaca, NY: Cornell University Press, 1985).
4. Steven Kelman, Regulating America, Regulating Sweden: A comparative study of occupational safety and health policy (Cambridge, MA: MIT Press, 1981).
5. Lennart J. Lundqvist, The Hare and the Tortoise: Clean air policies in the United States and Sweden (Ann Arbor: University of Michigan Press 1980).
6. David Vogel, National Styles of Regulation: Environmental policy in Great Britain and the United States (Ithaca, NY: Cornell University Press, 1986).
7. Jack Hayward and Robert Berki, State and Society in Contemporary Europe (Oxford: Robertson, 1979).
8. Joseph Nye, Philip Zelikow and David King (eds.), Why People Don't Trust Government (Cambridge, MA: Harvard University Press, 1997).
9. Roger Kasperson, Ortwin Renn, Paul Slovic et al., "The social amplification of risk: A conceptual framework", 8 Risk Analysis (1988), pp. 177-187.
10. Ragnar E. Lofstedt and David Vogel, "The changing character of regulation: A comparison of Europe and the United States", 21 Risk Analysis (2001), pp. 399-406.
11. Ragnar E. Lofstedt, "The impact of the Cox-2 inhibitor issue on perceptions of the pharmaceutical industry: Content analysis and communication implications", 12 Journal of Health Communication (2007), pp. 471-491.
12. Giandomenico Majone and Michelle Everson, "Institutional reform: Independent agencies, oversight, coordination and procedural control", in Olivier DeSchutter, Notis Lebessis and John Paterson (eds.), Governance in the European Union (Luxembourg: Office for the Official Publications of the European Communities, 2001).
13. European Commission, European Governance: A white paper, COM 2001 428 Final (Brussels: European Commission, 2001).
14. UK Strategy Unit, Risk: Improving Government's Capability to Handle Risk and Uncertainty-summary report (London: Strategy Unit, Cabinet Office, 2002).
15. European Commission, European Governance: A white paper, COM 2001 428 Final (Brussels: European Commission 2001).
16. UK Strategy Unit, Risk: Improving Government's Capability to Handle Risk and Uncertainty-summary report (London: Strategy Unit, Cabinet Office, 2002).
17. Archon Fung, Mary Graham and David Weil, Full Disclosure: The perils and promise of transparency (Cambridge: Cambridge University Press, 2007).
18. Mary Graham, Democracy by Disclosure: The rise of technopopulism (Washington DC: Brookings Press, 2002).
19. UK Food Standards Agency, Consumer Attitudes Survey 2002 (London:UK FSA, 2003).
20. Philip J. Hilts, Protecting America's Health: the FDA, business and one hundred years of regulation (New York: Knopf, 2003).
21. Roy Vagelos and Louis Galambos, Medicine, Science and Merck (Cambridge: Cambridge University Press, 2004).
22. Jerry Avorn, Powerful Medicines: The benefits, risks and costs of prescription drugs (New York, NY: Knopf, 2004).
23. Howard Brody, Hooked: Ethics, the medical profession and the pharmaceutical industry (Lanham, MD: Rowman and Littlefield, 2007).
24. Tom Nesi, Poison Pills: The untold story of the Vioxx drug scandal (New York, NY: St Martin's Press, 2008).
25. Marcia Angell, The Truth About the Drug Companies (New York, NY: Random House Trade Paperbacks, 2005).
26. Alexander S.D. Spiers, "Save the FDA", 330 BMJ (2005), at p. 308.
27. Jerry Avorn, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (New York, NY: Alfred A. Knopf, 2004).
28. Ragnar E. Lofstedt, "The impact of the Cox-2 inhibitor issue on perceptions of the pharmaceutical industry: Content analysis and communication implications", 12 Journal of Health Communication (2007), p. 471-491.
29. Chuck Grassley, Floor statement of U.S. Senator Chuck Grassley of Iowa, FDA Legislation, 26th July (2007).
30. Institute of Medicine, The Future of Drug Safety: Promoting and protecting the health of the public (Washington DC: National Academy of Sciences, 2006).
31. US Food and Drug Administration, FDA Acts to strengthen the safety program for marketed drugs-FDA Statement (Rockville: FDA, 5th November 2004).
32. Chuck Grassley, Opening Statement of U.S.Senator Chick Grassley of Iowa at the Hearing-FDA, Merck and Vioxx: Putting patient safety first? 18th November (2004).
33. Michael Leavitt, Leavitt: reforms will improve oversight and openness at FDA (Washington DC: HHS, 15th February 2005).
34. US Food and Drug Administration, FDA improvements in drug safety monitoring.-press release (Rockville, MD: FDA 2005).
35. Bruce M. Psaty, Sworn testimony before House Committee on Oversight and Government Reform (6th June 2007).
36. Institute of Medicine, The Future of Drug Safety: Promoting and protecting the health of the public (Washington, DC: National Academy of Sciences, 2006).
37. US Food and Drug Administration, The Future of Drug Safetypromoting and protecting the health of the public-FDA's response to the Institute for Medicine's 2006 Report (Rockville, MD: US FDA, 2006).
38. Bruce M. Psaty and Alta Charo, "FDA responds to Institute of Medicine Drug Safety Recommendations-In part", 297(17) Journal of the American Medical Association (2007), at p. 1919.
39. Bruce M. Psaty and David Korn, "Congress responds to the IOM drug safety report-in full", 298(18) Journal of the American Medical Association (2007), p. 2185-2187.
40. Food and Drug Administration's Amendments Act Title IX: Section 921, Adverse drug reaction reports and postmarket safety (Washington DC: US Congress FDAAA 2007).
41. Ricardo Alonso-Zaldivar, "Senate Oks drug-safety bill", Los Angeles Times, 21 September 2007, at p. A19.
42. Janet Woodcock, "FDA to post quarterly report of potential safety issues", US FDA Press Release, 5 September 2008.
43. Adam Burgess, Cellular Phones, Public Fears, and a Culture of Precaution (Cambridge: Cambridge University Press, 2003).
44. Ragnar E. Lofstedt, "Risk communication: The Avandia case, a pilot study", 3 Expert Review Pharmacology (2010), pp. 31-41.
45. Barry Meier, "For drug makers, a downside to full disclosure", New York Times, 23 May 2007.
46. Millett Granger Morgan, Baruch Fischhoff, Ann Bostrom et al., Risk Communication: A Mental Models Approach (New York, NY: Cambridge University Press, 2002).
47. Ragnar E. Lofstedt, "Public perceptions of the Mars sample return programme", 19 Space Policy (2003), pp. 283-292.
48. Millett Granger Morgan, Baruch Fischhoff, Ann Bostrom et al. Risk Communication: A Mental Models Approach (New York, NY: Cambridge University Press, 2002).
49. Earl Babbie, The Practice of Social Research (Florence, KY: Wadsworth Publishing, 1992).
50. Harris Interactive, "Confidence in FDA hits new low, according to WSJ.com/Harris interactive study", available on the Internet at (last accessed 17 January 2012).
51. House of Lords, Select Committee on Science and Technology: Science and Society. 3rd Report (London: Stationary Office, 2000).
52. Harris Interactive, "2007a. Large numbers of people do not trust the institutions they identify as most responsible for drug safety", available on the Internet at (last accessed 17 January 2012).
53. Roger E. Kasperson, Ortwin Renn, Paul Slovic et al., "The social amplification of risk: A conceptual framework", 8 Risk Analysis (1988), p. 177-187.
54. Nick Pidgeon, Rorger E.Kasperson and Paul Slovic (eds.), The Social Amplification of Risk (Cambridge: Cambridge University Press, 2003).
55. Jared A. Favole, "FDA unveils list of 20 drugs in side-effect probes", Wall Street Journal, 6th September 2008, at p.A4.
56. Daniel Kahneman and Amos Tversky, "Prospect Theory: An Analysis of Decision Under Risk", 47 Econometrica (1979), p. 263-291.
57. FDA Risk Communication Advisory Committee, "Minutes of Public Advisory Committee Meeting. August 14-15 2008", available on the Internet at (last accessed 17 January 2012).
58. Paul Seligman, "In Food and Drug Administration", FDA Communication of Drug Safety Information. (Rockville, MD: FDA, 7th December 2005).
59. Steven Galson, "Remarks made at the US Food and Drug Administration Centre for Drug Evaluation and Research", FDA'S Communication of Drug Safety Information, (Rockville, MD: FDA, 2008), at p. 8.
60. US Food and Drug Administration, Guidance: Drug safety information-FDA's communication to the public (Rockville, MD: FDA, 2007).
61. US Food and Drug Administration, FDA Announces new advisory committee to address risk communication (Rockville, MD: US FDA, 2007).
62. Harris Interactive. "Confidence in FDA hits new low, according to WSJ.com/Harris interactive study", available on the Internet at (last accessed on 17 January 2012).
63. Chuck Grassley, "Floor statement of U.S. Senator Chuck Grassley of Iowa", FDA Legislation (26th July 2007).
64. Ragnar E. Lofstedt, "Risk communication and management in the twenty-first century", 7 International Public Management Journal (2004), pp. 335-346.
65. UK Food Standards Agency, Consumer Attitudes Survey 2002 (London: UK FSA, 2003).
66. Christopher Hood, "Transparency in historical perspective", in Christopher Hood and David Heald (eds.), Transparency: The key to better governance?, Proceedings of the British Academy, vol. 135, p. 3-23.
67. Onora O'Neill, A Question of Trust: The BBC Reith lectures 2002 (Cambridge: Cambridge University Press, 2002).
68. Onora O'Neill, "Transparency and the ethics of communication", in Christopher Hood and David Heald (eds.), Transparency: The key to better governance?, Proceedings of the British Academy Vol. 135, p. 75-90.
69. Richard Horton, MMR Science and Fiction: Exploring the vaccine crisis (London: Granta, 2004).
70. Robert J. Fisher, "Social Desirability Bias and the Validity of Indirect Questioning", 20(2) The Journal of Consumer Research (1993), at p. 303.
71. Ragnar E. Lofstedt, "The Avandia case, a pilot study", 3 Expert Review Pharmacology (2010), pp. 31-41.
72. Robert J. Fisher, "Social Desirability Bias and the Validity of Indirect Questioning", 20(2) The Journal of Consumer Research (1993), at p. 303.2
73. Robyn Dawes, "Judgment and choice", in Daniel Gilbert, Susan Fiske and Gardner Lindzey (eds.), Handbook of Social Psychology (New York: McGraw and Hill, 1998).
74. Lars Osterberg and Terrence Blaschke, "Adherence to Medication", 353 New England Journal of Medicine (2005), pp. 487-497.
75. Paul Slovic, The Perception of Risk (London: Earthscan 2000).
76. Aliya Sternstein, "FDA's web overhaul won't inform public, critics say", National Journal's Technology Daily, 16 April 2007.
77. Amos Tversky and Daniel Kahneman, "Availability: A heuristic for judging frequency and probability", 5 Cognitive Psychology (1973), pp. 207-232.
78. Amos Tversky and Daniel Kahneman, "Judgment under uncertainty: Heuristics and biases", 185 Science (1974), pp. 1124-1131.
79. FDA Risk Communication Advisory Committee, "Minutes of Public Advisory Committee Meeting. August 14-15 2008", available on the Internet at (last accessed 17 January 2012).
80. Paul Slovic, "Perceived risk, trust and democracy", 13 Risk Analysis (1993), pp. 675-682.
81. Baruch Fischhoff, "Risk perception and communication unplugged: Twenty years of process", 15 Risk Analysis (1995), pp. 137-145.